• 1.

    Kahn SE , et al.. Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future. Lancet 2014; 383:10681083.

  • 2.

    Andersen ES , et al.. Do we know the true mechanism of action of the DPP-4 inhibitors? Diabetes Obes Metab 2018; 20:3441.

  • 3.

    Davies MJ , et al.. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41:26692701.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Davidson JA . The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes. Endocr Pract 2013; 19:10501061.

  • 5.

    Tkac I , Raz I . Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care 2017; 40:284286.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Lee SG , et al.. Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. JAMA Dermatol 2019; 155:172177.

  • 7.

    Deacon CF , Lebovitz HE . Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab 2016; 18:333347.

  • 8.

    Rosenstock J , et al.. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 2015; 38:376383.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Cooper ME , et al.. Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis 2015; 66:441449.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Groop PH , et al.. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: The randomized MARLINA-T2D trial. Diabetes Obes Metab 2017; 19:16101619.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Rosenstock J , et al.. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial. JAMA 2019; 321:6979.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Marx N , et al.. Design and baseline characteristics of the CARdiovascular Outcome trial of LINAgliptin versus glimepiride in type 2 diabetes (CAROLINA®). Diab Vasc Dis Res 2015; 12:164174.

    • PubMed
    • Search Google Scholar
    • Export Citation

Dipeptidyl Peptidase-4 Inhibitors

Muhammad Maqbool Muhammad Maqbool and Mark E. Cooper are with the Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.

Search for other papers by Muhammad Maqbool in
Current site
Google Scholar
PubMed
Close
and
Mark E. Cooper Muhammad Maqbool and Mark E. Cooper are with the Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.

Search for other papers by Mark E. Cooper in
Current site
Google Scholar
PubMed
Close
Restricted access
Save